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Novel translational approaches to the search for precision 
therapies for acute respiratory distress syndrome
Nuala J Meyer, Carolyn S Calfee
In the 50 years since acute respiratory distress syndrome (ARDS) was first described, substantial progress has been 
made in identifying the risk factors for and the pathogenic contributors to the syndrome and in characterising the 
protein expression patterns in plasma and bronchoalveolar lavage fluid from patients with ARDS. Despite this effort, 
however, pharmacological options for ARDS remain scarce. Frequently cited reasons for this absence of specific drug 
therapies include the heterogeneity of patients with ARDS, the potential for a differential response to drugs, and the 
possibility that the wrong targets have been studied. Advances in applied biomolecular technology and bioinformatics 
have enabled breakthroughs for other complex traits, such as cardiovascular disease or asthma, particularly when a 
precision medicine paradigm, wherein a biomarker or gene expression pattern indicates a patient’s likelihood of 
responding to a treatment, has been pursued. In this Review, we consider the biological and analytical techniques that 
could facilitate a precision medicine approach for ARDS.
Introduction
In the 50 years since Ashbaugh and colleagues1 first 
described acute respiratory distress syndrome (ARDS), 
substantial progress has been made in identifying 
the pathogenic contributors to the syndrome and in 
improving the ventilatory support of patients.2 Con­
current improvements in the management of sepsis,3,4 
the most common precipitant of ARDS, and ventilator 
liberation, sedation practices, and preventive therapies,5,6 
have also contributed to the improved survival of patients 
with ARDS. Nonetheless, in observational studies7,8 from 
across the world, the mortality of patients with ARDS 
remains high; about one in three patients diagnosed with 
ARDS will not survive 60 days. Pharmacological 
treatments for ARDS remain scarce, with only one drug 
(cisatracurium besilate) showing a potential, albeit 
probably non­specific, benefit in a randomised trial of 
340 patients.9 The need for new therapies for ARDS is 
indisputable, yet numerous well conceived studies have 
been unable to identify an effective treatment.10–14 Drugs 
might have been ineffective because responses to, or the 
toxic effects of, therapy are non­uniform; because of 
problems with drug timing, duration, or delivery; or 
because of incomplete understanding of the pathogenesis 
or heterogeneity of ARDS.15–17 A precision approach, 
whereby therapies are specifically targeted to patients 
most likely to benefit, might overcome such limitations 
and is broadly advocated for ARDS.18,19 In this Review, we 
consider tools and approaches that might facilitate the 
identification of novel and potential precision therapies 
for ARDS by identifying the mechanisms and therapeutic 
relevance of specific biological pathways, by identifying 
subgroups of patients likely to respond to a particular 
therapy based on their biology, or (perhaps ideally) both.
Discovery and bias-free approaches to identify 
new biological mechanisms and drug candidates 
in ARDS
Substantial inflammation in the alveolar and plasma 
compartments has been a recognised characteristic of 
patients with ARDS since the 1980s. High concentrations 
of inflammatory cytokines have been associated with both 
injurious ventilator strategies and worse outcomes.20–23 
Beyond inflam mation, mechanisms including endothelial 
activation, respiratory epithelial dysfunction, and sur­
factant depletion have been established as major 
contributors to the pathogenesis of ARDS,24,25 and 
candidate studies26–30 of individual biomarkers and genes 
in these pathways have yielded and continue to yield 
some important associations (table 1). Novel analytical 
tech niques to be discussed in this Review might highlight 
new uses for some of these accepted markers to refine 
ARDS endotypes or to serve as enrichment markers in 
future trials. To date, however, improved molecular 
understanding of the pathogenic contributors to ARDS 
has yet to translate into mortality reductions for patients 
with the syndrome.
How could a paradigm­shifting breakthrough be 
facilitated? Perhaps the field of ARDS has persisted in 
looking under the light, restricting inquiry to genes and 
proteins already hypothe sised to affect lung injury.39 
Key messages
•	 Effective	pharmacotherapies	for	acute	respiratory	distress	
syndrome	(ARDS)	are	still	elusive,	and	the	clinical	and	
biological	heterogeneity	of	ARDS	suggests	that	precision	
approaches	might	be	helpful.
•	 Novel	approaches	to	understanding	ARDS	biology,	
identifying	discrete	subgroups	of	ARDS,	or	both	are	
needed to facilitate precision therapies for ARDS.
•	 Discovery-based	approaches,	combined	with	candidate	
marker analyses, might help to identify new pathways 
relevant	to	ARDS	for	subsequent	testing	in	
hypothesis-driven	experiments,	potentially	including	
novel preclinical models of ARDS.
•	 New	approaches	to	analyses	of	complex	clinical	and	
biological data might help to identify distinct ARDS 
subgroups	that	might	be	suitable	for	targeted	therapies.
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Although continued investigation of selected candidate 
pathways, identified from experimental and obser­
vational investigations of ARDS, does and should 
continue, a complementary approach is to use discovery 
methods independent of any understanding of the 
pathogenesis of ARDS. Such “bias­free” approaches 
include assessing large­scale variation in genomic 
DNA, transcriptome (mRNA) expression, non­coding 
RNA, proteins, lipids, or metabolites and comparing 
patients with ARDS with at­risk controls. Generally, the 
goal of such approaches is to identify novel candidates 
that can then be investigated in more traditional 
hypothesis­testing experiments (figure 1). We stress 
that discovery approaches are not inherently superior to 
hypothesis­driven, candidate investigations, but rather 
that discovery approaches can bring new candidates to 
the pipeline of investigation. Discovery approaches are 
not predicated on our current understanding of ARDS 
biology but rather on the investigator’s ability to select 
representative biospecimens and populations of 
patients and unaffected controls. Thus, such approaches 
are free from the biases introduced by our current 
molecular understanding of ARDS, such as which 
pathways are activated and which molecules incite or 
perpetuate lung injury. We refer to discovery approaches 
as bias­free when they are also independent of known 
genetic or proteomic sequences; for example, 
sequencing is bias­free, whereas a whole­genome gene 
expression array requires knowledge about transcripts 
to design specific probes (table 2). Although a sceptic 
might view discovery approaches as akin to a fishing 
expedition, the broad goal of these studies is not to 
merely identify the most discriminatory marker 
between samples, but also to expand our consideration 
of pathways and mechanisms not presently thought to 
contribute to disease and to explain why an unexpected 
marker might differ significantly between cases and 
non­cases or between target tissues.
Figure 1: Integrative approaches to identify and test new precision therapies for acute respiratory distress syndrome
Observations	made	from	candidate	and	discovery	methods	fuel	traditional	hypothesis	testing	and	inform	novel	
designs	such	as	EVLP	or	lung-on-a-chip.	Drug	candidates	with	a	consistent	signal	for	benefit	across	multiple	study	
designs are	the	most	promising	for	biomarker-enriched	clinical	trials.	EVLP=ex-vivo	lung	perfusion.	
CRISPR=clustered	regularly	interspaced	short	palindromic	repeats.	CAS9=CRISPR-associated	protein	9.
Precision 
clinical trials
Causal inference, 
systems biology analyses
Novel analytical techniques
• Machine learning
• Latent class analysis
• Causal inference
Discovery methods 
(”Omics”) and candidate 
marker analyses
Phenotype observations 
(clinical, radiographics, 
biological)
Traditional and novel experimental designs 
(EVLP, lung-on-a-chip, CRISPR/CAS9)
Iterative 
hypothesis 
testing
Genes (DNA) Transcripts 
(RNA)
Metabolites Proteins (biomarkers)
Inflammation CXCL8 (IL8), IL6, IL1B, TNF, CSF2 (GM-CSF), 
IL10, IL1RN, MBL2, NFKBIA, TIRAP, TLR1, PI3, 
IRAK3, DARC, ADIPOQ
IL1R2, FTL, PI3, 
S100A2
·· IL8,	IL6,	IL1B,	IL18,	CSF2	(GM-CSF),	CSF3	(G-CSF),	
TNFRSR1A	(sTNFR1),	IL10,	TNF	(TNF-α)
Endothelial	injury	or	function ANGPT2, TEK (TIE2), ACE, NAMPT (PBEF) 
VEGFA, DIO2, PLAU, SERPINE1 (PAI1), MYLK, 
SIP3, FVL
·· Sphingomyelin ANGPT1	(ANG1),	ANGPT2	(ANG2),	VEGF-A,	VWF,	
apolipoproteins,	cell-free	haemoglobin,	PAI1,	endothelial	
glycocalyx,	THBD	(sTM),	ICAM1	(sICAM),	PROC
Epithelial	injury	or	function SFTPB, EGF ·· ·· AGER	(sRAGE),	SFTPD,	FGF7	(KGF),	HGF,	SCGB1A	(CC16),	
MUC1	(KL6)
Extracellular	matrix	injury ·· ·· Desmosine	(urine) COL1A2	(PCPII),	COL3A1	(PCP	III)
Platelet	count	or	function LRRC16A ·· ·· ··
Oxidant	stress	pathway HMOX1, HMOX2, NFE2L2 (NRF2), NQO1 ·· Glutathione,	nitric	oxide	(urine) ··
Iron homoeostasis HMOX1, HMOX2 FTL ·· FTL,	FTH1
Apoptosis FAS ·· Phosphatidylserine FASLG	(FASL)
Purine	metabolism ·· ·· Hypoxanthine,	xanthine,	guanosine ··
Urea cycle ·· ·· Glutamate,	creatinine,	creatine ··
Glycolysis	or	carbohydrate	
metabolism
·· ·· Lactate,	citrate,	adenosine ··
Lipid	metabolism ·· ·· Phosphatidylcholine,	
sphingomyelin
Apolipoproteins
Unclassified	role	in	ARDS PPFIA, POPDC3, FAAH, XKR3, ASRD ·· ·· ··
Genes	and	transcripts	are	shown	by	their	HUGO	gene	nomenclature	committee	symbol,	with	a	common	alternative	name	in	parentheses	if	appropriate.26,27,30–33 Metabolites34,35 and proteins17,29,36–38	are	shown	using	
Reference	Sequence	abbreviations,	with	common	alternative	names	in	parentheses.	ARDS=acute	respiratory	distress	syndrome.
Table 1: Selected key biological features, and their related pathways, associated with ARDS risk or mortality by candidate and discovery approaches
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Genome-wide association studies
Genome­wide association studies attempt to find regions 
of the genome in which genetic variation among 
unrelated cases is consistently skewed compared with 
the background population.40 An extension of classic 
family­based genetic linkage studies, genome­wide 
association studies rely on very large populations to 
detect common genetic variants with small­to­moderate 
effect sizes and stipulate an extreme statistical imbalance 
(p values of less than 5 × 10–¹⁸) to declare significance. 
One genome­wide association study of trauma­
associated ARDS has been reported;41 no single­
nucleotide polymorphism (SNP) achieved genome­wide 
significance, although a replicating variant in the liprin­α 
gene that warrants further mechanistic investigation 
was identified. This first attempt at a genome­wide 
association study of ARDS was instructive for 
highlighting its insufficient power despite including 
600 patients with ARDS and more than 2000 healthy 
controls in a discovery population, followed by an 
additional 500 critically ill patients in a replication 
population.41 Although a genome­wide association study 
is a powerful tool with reasonable consensus about 
analytical strategy, additional consid erations might 
restrict its application to a trait such as ARDS. For 
example, although ARDS is the cause of many thousands 
of deaths each year, clinical recognition of ARDS is poor,7 
and no validated method exists to diagnose ARDS with 
electronic medical record coding.42 Additionally, because 
ARDS is a complication of serious insults, such as 
sepsis, pneumonia, aspiration, trauma, and ventilator 
exposure,8 the use of healthy controls can be problematic. 
Controls carrying a high­risk genetic variant might not 
develop ARDS if they do not develop sepsis, and thus 
would be classified as non­cases, attenuating any 
potential association signal.43 By selecting controls with a 
risk factor for ARDS, studies might be less susceptible 
to potential misclassification. Similarly, when evaluating 
variants for association with ARDS mortality, it would be 
reasonable to require that both cases and controls have 
ARDS. Few populations exist that are adequately 
powered to test or replicate genome­wide ARDS variants. 
Further more, heterogeneous patients are currently 
labelled as ARDS cases despite different precipitants, 
sites of injury, and biological profiles. Combining such 
patients in an effort to maximise sample size might have 
the unfortunate effect of drowning out statistical signals 
that might only be active in one subset of the 
population.15,26,36,44
Next-generation sequencing
Whereas genome­wide association studies search for 
common variants that are involved in common diseases, 
each variant conferring just a small fraction of altered 
risk, rare­variant analyses use DNA sequencing to 
detect polymorphisms that could have a large effect but 
are highly uncommon.45 Sequencing of genomic coding 
regions (so­called exome sequencing) was done in a 
collaborative effort sponsored by the National Heart, 
Lung, and Blood Institute46 and included 96 cases of 
ARDS. When ARDS cases were compared with 
presumably healthy controls in the 1000 Genomes 
Project, two SNPs in the genes XK related 3 and 
arylsulfatase D showed differential expression in ARDS 
cases,31 although both findings still require replication. 
Perhaps surprisingly, exome sequencing, which aims to 
Hypothesis testing 
(candidate)
Medium-to-high-throughput discovery Bias-free discovery
DNA (genomics) 
Genomic	DNA	(all	cells	the	same);	somatic	
DNA	(eg,	tumour,	individual);	epigenomics	
(methylation, acetylation)
Candidate	genotyping;	
methylation-specific	PCR
DNA	array;	genome-wide	association	studies;	
bisulfite-array	(methylation	status)
Next-generation	sequencing;	chromatin-
immunoprecipitation	sequencing	(protein–DNA	binding	
sites)*;	bisulfite	sequencing	(methylation	sites)†
RNA‡ (transcriptomics)
Transcriptome;	mRNA	or	cDNA;	miRNA;	
ncRNA
Candidate	PCR cDNA	microarray	(also	known	as	gene	expression	
microarray)
RNA	sequencing
Proteins‡	(proteomics) Candidate	(antibody-based)	
ELISA;	western	blot
Multiplex	ELISA;	bead-based	assays;	DNA-aptamer	
array
MALDI-TOF	mass	spectrometry
Metabolites§ (metabolomics)
	Aminoacids;	carbohydrates;	lipids;	
glycoproteins;	peptidoglycans;	small	
molecules;	drugs	or	toxins
Target	gas	chromatography-
mass spectrometry
Gas,	liquid,	or	solid	chromatography	(for	
separation);	mass	spectrometry	or	nuclear	
magnetic resonance spectroscopy (for detection)
Gas,	liquid,	or	solid	chromatography	(for	separation);	
mass	spectrometry	or	nuclear	magnetic	resonance	
spectroscopy (for detection)
Microbiota Candidate	PCR;	culture	
detection
Targeted	amplicon	sequencing Next-generation	sequencing	(also	known	as	
metagenomics)
We	refer	to	candidate	testing	when	an	individual	known	entity	(SNP,	specific	transcript,	protein,	etc)	is	quantified,	whereas	medium-throughput	or	high-throughput	discovery	approaches	rely	on	known	features	
but	are	capable	of	multiplex	assays.	For	example,	genome-wide	association	studies	or	cDNA	microarrays	rely	on	the	knowledge	of	a	genetic	sequence	to	generate	probes	that	will	assay	each	SNP	or	transcript.	
By	contrast,	bias-free	methods	imply	that	the	features	being	detected	might	be	unknown—for	example,	next-generation	sequencing	sequences	all	nucleic	acids	detected,	regardless	of	whether	a	sequence	is	
recognised.	MALDI-TOF=matrix-assisted	laser	desorption/ionisation	time-of-flight.	cDNA=complementary	DNA.	miRNA=microRNA.	ncRNA=non-coding	RNA.	SNP=single-nucleotide	polymorphism.	
*Chromatin-immunoprecipitation	sequencing	is	a	method	to	detect	and	sequence	areas	of	the	genome	where	proteins	interact	with	DNA	to,	for	example,	understand	transcription	factor	binding.	†Bisulfite	
sequencing	is	a	method	that	uses	bisulfite	treatment	of	DNA	to	uncover	DNA	methylation	patterns	that	might	give	clues	to	DNA	regulation.	‡Vary	by	cell	type	and	time.	§Vary	by	location	and	time.
Table 2: Candidate and discovery methods to interrogate different biological features
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detect major deleterious genetic disruptions, has shown 
that, for a fraction of the population, the clinical pheno­
type is explained by multiple major genetic variants 
rather than just one.47 The potential for multiple 
variants that affect ARDS coexisting in one patient is 
even more relevant for common (non­coding) genetic 
variation and, if unrecognised, this issue might 
contribute to imprecise risk estimates or restricted 
reproducibility.
Gene expression profiling
The search for new candidates involved in the patho­
genesis of ARDS is not restricted to genomic DNA. 
Discovery approaches exist to interrogate transcript 
expression (so­called transcriptomics), DNA modifi­
cations (so­called epigenomics), proteins, metabolites, 
and microbiota. The key technological shift that 
facilitated the explosion of these ‘omic fields was the 
ability to perform high­throughput feature capture and 
identification without a­priori designation of which 
features would be sampled. In the case of tran­
scriptomics, in which mRNA is the feature under 
investigation, the field has progressed from whole­
genome arrays—ie, microchips coated with thousands 
of oligonucleotide probes specific to the complementary 
DNA (cDNA) sequence of roughly 22 000 known 
genes—to RNA sequencing, whereby cDNA or 
occasionally RNA is sequenced using next­generation 
sequencing technology.48 The main advantage of RNA 
sequencing compared with microarrays is that RNA 
sequencing does not rely on probes designed to capture 
cDNA variation based on previous knowledge of the 
genome, but instead applies sequencing to all cDNA 
captured from the sample.49 As a result of RNA 
sequencing investigations, we are gaining insight into 
the regulatory roles of non­coding RNA and small RNA 
species, the potential for alleles that do not change 
protein sequence to affect expression, and the 
complexity involved in isoform determination.50 The 
challenges involved in applying RNA sequencing to a 
phenotype such as ARDS are not trivial and can be 
summarised as obstacles facing the broad field of 
transcriptomics—including developing bioinformatic 
solutions to high­dimensional data analysis, quality 
assurance, and achieving a consensus on significance 
testing—and burdens that might be unique to ARDS. 
Burdens unique to ARDS are fundamental questions 
about study design: which tissue(s) should be profiled 
by RNA sequencing to discover new markers and 
inform about ARDS pathogenesis? Lung tissue is so 
rarely available while the patient is alive with early 
ARDS,51 so are alveolar macrophages an adequate 
substitute? Kovach and colleagues52 reported the first 
microarray analysis of human alveolar macrophages 
collected from broncho alveolar lavage fluid samples 
from patients with early ARDS (days 0–4) and identified 
a pattern of relative immune tolerance distinguishing 
ARDS­derived alveolar macro phages from those of 
healthy controls. Although the contribution of alveolar 
macrophages in lung host defence, injury, and reso­
lution is established,53 it would seem unwise to ignore 
the potential contributions of lung­resident neutrophils 
and lymphocytes, as well as the endothelial, epithelial, 
and stromal cells of the lungs. Attempts to characterise 
gene expression in whole­blood or circulating mono­
nuclear cells have also been done for ARDS54,55 and have 
implicated dysregulation in neutrophil­expressed genes 
and the ferritin heavy chain, although these findings 
await replication.
Discovery proteomics and metabolomics
High­throughput approaches are also feasible for 
analysing the expression patterns of proteins or small­
molecule metabolites in body fluid or tissue. Rather than 
attempting to quantify a protein or molecule of known 
identity, these techniques first separate the population of 
unknown proteins or small molecules, then quantify 
and identify them. Advances in the granular separation 
of proteins or small molecules with differential light 
absorption and activation (ie, matrix­assisted laser 
desorption/ionisation time­of­flight [MALDI­TOF] mass 
spectrometry), and the resolution of compounds with 
gas and liquid chromatography, have led to substantial 
improvements compared with two­dimensional gel 
electrophoresis. Additionally, mass spectrometry and 
nuclear magnetic resonance spectroscopy have improved 
the accuracy and sensitivity of the identification 
of unknown proteins and metabolites.56 A high­
dimensional proteomic analysis57 of bronchoalveolar 
lavage fluid from patients with ARDS identified 
differential protein expression between ARDS survivors 
and non­survivors over the first 4 days of ARDS, with 
non­survivors manifesting decreased expression of 
proteins related to coagulation, iron homoeostasis, and 
immune activation and increased expression of proteins 
related to glycolysis, collagen metabolism, and the actin 
cytoskeleton. High­throughput proteomic screening of 
plasma from patients with ARDS identified increased 
expression of glyco proteins and serum amyloid A and 
decreased expression of complement factor H and 
apolipoprotein A, B, and C compared with plasma from 
healthy controls.58 However, discovery proteomics in 
lung injury has been hampered by several factors, 
including the complexity of the plasma proteome and 
overwhelming signals from high­abundance plasma 
proteins (eg, albumin), which have limited the insights 
gained to date;59 thus, most of the recent advances in this 
area have come from candidate marker analyses. Indeed, 
the expectation is that each promising feature identified 
through a discovery approach should then be replicated 
as a candidate marker, as is highlighted by the iterative 
example in figure 1; the most compelling associations 
will show converging support from multiple lines of 
evidence.
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Large­scale metabolomics has also been done with 
both bronchoalveolar lavage fluid and plasma from 
patients with ARDS compared with healthy controls.34,35 
Whereas both bronchoalveolar lavage fluid and plasma 
showed increased expression of lactate, citrate, and 
creatine, other metabolites were specific to each fluid. 
For example, bronchoalveolar lavage fluid from patients 
with ARDS was characterised by increased expression 
of guanosine, xanthine, and hypoxanthine—metabolites 
of guanosine and uric acid metabolism pathways—and 
decreased expression of phosphati dylcholines, the 
phospho lipids that constitute pulmonary surfactant.34 
Plasma from patients with ARDS was characterised 
by metabolites that might indicate disrupted 
oxi dant stress signalling (glutathione), energy homoeo­
stasis (adenosine), endothelial barrier function 
(sphingomyelin), and apoptosis (phosphati dylserine).35 
Although exciting, each of these proteomic and 
metabolomic investigations were done with very 
small sample sizes (n<20 individuals), and the direct 
translation from protein or metabolite identification to 
ARDS diagnosis or therapy is not obvious.34,35,57,58 By 
contrast, another group examined the metabolome of 
exhaled breath condensate collected from the ventilators 
of more than 100 critically ill patients and identified 
three volatile compounds—octane, acetaldehyde, and 
3­methylheptane—in the exhaled breath condensate of 
patients with ARDS compared with ventilated controls.60 
By use of training and validation sets, the authors of 
that study showed that these three metabolites had a 
reasonable diagnostic performance on their own and 
that dis crimination was improved when they were 
added to the Lung Injury Prediction score compared 
with the score used alone.60–62
Microbiome analysis
The lung microbiome represents another opportunity to 
apply cutting­edge sequencing techniques in a bias­free 
manner. Dickson and colleagues63 showed that, in a 
mouse model of sepsis induced by caecal ligation and 
puncture, the lung microbiota was rapidly modified by 
sepsis and gut­associated bacteria were the dominant 
community for 5 days. The gastrointestinal tract, and not 
the upper respiratory tract, was shown to be the source of 
sepsis­induced lung microbiome alterations for mice 
with sepsis from systemic insults, whereas this shift 
from typical lung­resident microbes to gut­associated 
bacteria was not observed in mice exposed to intratracheal 
lipopolysaccharide to model direct lung injury.63 In 
support of these findings,63 sequencing of bacterial 
ribosomal RNA from the bronchoalveolar lavage fluid 
of 68 patients with ARDS identified gut­associated 
Bacteroides species in 28 (41%) patients, compared with 
only one (3%) of 26 healthy controls. Enrichment of gut 
bacteria in bronchoalveolar lavage fluid was associated 
with the plasma concentration of inflammatory markers. 
Thus, for non­pulmonary sepsis­associated ARDS, 
translocation of bacteria from the gut to the lungs might 
have a more prominent role than previously recognised, 
because traditional culture methods are relatively 
insensitive to anaerobic bacteria. Whether this mech­
anism can be targeted to prevent or treat ARDS, however, 
remains untested.
New analytical approaches
As the potential for each ‘omic method to be applied to 
ARDS is considered, the sheer volume of data generated 
is potentially staggering. How should this wealth of 
biological data, often coupled with extensive clinical data 
from the critical care setting, be analysed to maximise 
our potential insight into novel treatment approaches for 
ARDS? Even for candidate marker analyses, novel 
analytical approaches might be needed to maximise the 
insight gained and integrate with complex molecular and 
clinical data. Traditionally, biological data from human 
beings with ARDS have been analysed in one of two 
ways: by identifying the biological phenotypes most 
strongly associated with a clinical outcome of interest 
(often death), with the idea that targeting these pathways 
might thereby reduce mortality, or by dividing patients 
into categories based on clinically evident or pre­
supposed characteristics and then comparing their 
clinical and biological phenotypes to identify distinct 
subgroups that might respond differently to treatment. 
A common approach has been to measure biomarkers 
thought to reflect specific biological pathways and test 
their association with poor outcomes, typically with 
regression­based methods. This approach is appealingly 
straightforward; it is intuitive and, at least in its simplest 
form, requires minimal advanced training in statistical 
analysis for either the investigator or the reader of the 
final product. Moreover, this approach has led to 
substantial advances in our understanding of the biology 
of human ARDS. Over the past three decades, studies 
ranging from small, single­centre investigations to 
secondary analyses of large multicentre clinical trials have 
reported associations between poor clinical outcomes 
and biomarkers of key pathways of lung injury—for 
example, injury to the lung epithelium and 
endothelium—as well as numerous inflammatory 
pathways. Although a comprehensive review of these 
studies is beyond the scope of this Review, several of the 
key studies are cited in table 1. This approach is 
particularly well suited to confirming the human 
relevance of biological pathways identified in laboratory 
models of ARDS. This approach has most commonly 
been used to analyse candidate plasma proteins and 
genetic polymorphisms, although more recent investi­
gations have focused on unbiased discovery methods 
such as DNA and RNA sequencing, metabolomics, and 
proteomics. This approach also has notable limitations. 
First and most important is the old adage that correlation 
does not imply causation; put differently, biological 
markers associated with mortality in ARDS might not be 
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causal drivers of ARDS mortality and, therefore, might 
not be good therapeutic targets. Studying these 
associations in the setting of a randomised trial, and 
incorporating analysis of the response of the biomarker 
in question to the randomly assigned therapy, might 
partially mitigate but not eliminate this issue.21 Second, 
the regression­based models typically used for these 
types of analyses do not mandate or necessarily facilitate 
analyses of heterogeneity within ARDS, so as to identify 
treatment­responsive subgroups. Alternative analytical 
approaches are better suited than regression methods for 
this particular question.
A second approach often applied to patient data to 
search for novel treatment strategies for ARDS is to 
divide patients into subgroups based on pre­existing 
hypotheses or clinically evident features and then to 
compare the biology of these subgroups. For example, 
for decades, investigators have focused on whether direct 
lung injury (ie, ARDS resulting from direct damage to 
the lung parenchyma, such as in pneumonia or aspiration 
of gastric contents) differs from indirect lung injury 
(ie, ARDS resulting from an insult distant to the lung 
parenchyma, such as non­pulmonary sepsis or massive 
blood transfusion).64 Clinical studies36,65 have supported 
this distinction, identifying differences in endothelial 
injury and inflammation between patients with direct 
and indirect lung injury. Other similar types of analyses 
have subdivided ARDS into diffuse versus focal radio­
graphic changes, or into subgroups based on clinical risk 
factors (eg, trauma vs sepsis vs other).66–68 Similar to 
outcome­focused methods, these approaches have the 
advantage of being intuitive and logical, particularly for 
clinicians who can recognise in their own practice the 
obvious clinical differences between subgroups of 
patients with different clinical features or natural 
histories. However, these approaches rely on our pre­
existing biases about disease classification and, to date, 
have not led to successful clinical trials targeting specific 
ARDS subgroups.
As our ability to quantify biological complexity has 
advanced over the past several decades, so too have novel 
statistical methods designed to disentangle heterogeneity 
within complex datasets. The use of these novel statistical 
methods in other disease phenotypes, such as asthma, 
has led to substantial progress towards the discovery of 
disease endotypes—that is, specific subgroups of a 
syndrome with distinct pathobiologies and differential 
responses to treatment. Some of these methods are now 
being used in translational studies of critical illness, with 
a similar goal.
Cluster­based methods encompass various analytical 
techniques that share the broad goal of identifying groups 
(clusters) of observations with similar characteristics. 
These types of methods, such as hierarchical clustering 
and κ­means clustering, have commonly been applied to 
genomic data, with the aim to identify clusters of patients 
with similar gene expression patterns. Once biological 
data has been used to identify patient clusters, the clusters 
can subsequently be analysed for differences in clinical 
outcomes, clinical phenotypes, or other variables of 
interest. Multiple examples exist of the use of these 
techniques in asthma, in which they have helped to 
identify the T­helper­2­high endotype in several studies.69,70 
In critical care, cluster­based methods have been used to 
identify subclasses of paediatric septic shock.71,72 These 
methods have several advantages, including an explicit 
focus on reducing heterogeneity by identifying subgroups 
that are internally similar, an unbiased approach free 
from presupposition, and facile visual representation 
(ie, the classic heat map). Another advantage for use of 
clustering in ARDS is that it can be done on baseline 
characteristics without consideration of outcome. 
However, one notable disadvantage of cluster­based 
methods is that they will always identify clusters73 and do 
not test a specific hypothesis regarding the number of 
clusters in a particular class. This parameter must be set 
externally and, as such, might be prone to bias regarding 
the number of clusters present, although methods exist to 
estimate the optimal number of clusters from the data.74
Another advanced analytical approach, which, similar 
to cluster analysis, often falls under the rubric of machine 
learning, is classification trees, often referred to as 
classification and regression tree analysis. This approach 
is designed to identify unexpected cut­points in a set of 
data that permit classification into subgroups that might 
not be readily apparent. This approach generates a 
branching tree­like structure that branches at specific 
cut­points of a given variable and ends in multiple 
terminal nodes, which are often distinguished by 
differences in outcomes. This method has the advantage 
of being able to identify patterns in the data that would 
otherwise be unapparent. However, classification trees 
are also notorious for overfitting the model to the data 
and, as such, mandate external validation in independent 
datasets. Tree­based models have been used in hospital 
inpatients to identify predictors of clinical deterioration,75 
in adult septic shock to refine prognostic stratification 
based on plasma biomarkers,76 and in ARDS to identify 
clinical features associated with poor outcomes.77 These 
trees are constructed based on the association between 
the measured variables and a specific clinical outcome, 
so the caveats regarding outcome­based models also 
apply to these trees—ie, that the variables which identify 
the branches in the tree might not be causally related to 
the observed differences in outcomes. Similar to cluster­
based models, tree­based models also require external 
and potentially arbitrary decisions regarding the number 
of branches and terminal nodes, although methods with 
re­sampling and cross­validation have been developed to 
inform these decisions.75
Latent class analysis is an approach derived from 
mixture modelling that is explicitly designed to identify 
hidden (so­called latent) subgroups within a larger 
group. Latent class analysis has been widely applied in 
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psychiatric research and has been an important 
contributor to the study of asthma endotypes.78,79 One 
major strength of latent class modelling is that it can 
test the hypothesis that a certain number of classes (k) 
fits the data better than one fewer class (k – 1), providing 
more objective confirmation of the optimal number of 
classes for a given dataset. In ARDS, use of latent class 
analysis has identified two distinct subphenotypes in 
independent analyses of three randomised trials.15,17 
The two sub phenotypes were clearly distinguished in 
part on the basis of biomarker profiles, with one sub­
phenotype characterised as hyper­inflammatory com­
pared with the other subphenotype, and by their 
responses to randomly assigned positive end­expiratory 
pressure and a fluid­conservative management strat­
egy. When applied to trauma cohorts, latent class 
analysis also identified distinct subgroups of ARDS 
that were distinguished largely by time to ARDS 
development, but also by clinical characteristics and 
plasma biomarker expression.80 One disadvantage of 
latent class analysis is that relatively large datasets 
(n>300 individuals) are typically needed to confidently 
fit latent class models.
Quantitative trait analysis 
Recognising that heterogeneity is a cardinal feature 
of ARDS that might confound traditional genomic 
approaches, an alternative approach is to apply genomic 
tools (eg, genome­wide association studies) to an 
intermediate trait that has meaning in the context of 
ARDS (eg, a plasma biomarker or expression of an 
mRNA transcript) to apply causal inference methods 
that might help to evaluate one aspect of the syndrome. 
For example candidate studies81–83 have shown plasma 
concentrations of angiopoietin­2 (ANG2)—a protein 
secreted by activated endothelium that potentiates 
vascular permeability—to be a strong marker for ARDS 
diagnosis, prediction, and prognosis. Discovery genetic 
approaches also implicate this pathway in ARDS risk,84 
making ANG2 an attractive candidate ARDS 
intermediate protein. If we consider that every biological 
process is, to some degree, controlled by our DNA, the 
genetic regulation of a plasma protein such as ANG2 is 
far less complex than that of ARDS, because the 
phenotype of plasma ANG2 concentration is regulated 
by fewer genes and has a stronger correlation between 
genetic variation and measured output (ANG2) than 
does a disease phenotype such as ARDS. Thus, the 
likelihood of finding genetic variants that explain a high 
proportion of variance in plasma ANG2 concentration is 
greater than finding variants that explain a large 
proportion of ARDS risk.50 Furthermore, quantitative 
traits are statistically more powerful than dichotomous 
traits, such that statistically significant results might be 
detected with only 100 or 200 patients, rather than with 
the 1000s necessitated by traditional genome­wide 
association studies,85 and such sample sizes are far 
more achievable for populations of critically ill patients. 
Genomics can then be used to apply causal inference 
methods—techniques borrowed from the econometric 
and social science fields—to infer causality from 
observational data. The advantage of identifying causal 
biomarkers in ARDS, rather than markers that merely 
correlate with ARDS, is that modifying the causal 
intermediate is more likely to influence disease 
outcome. Experimental evidence from animal or in­
vitro models allows us to directly test whether 
intermediates have direct causal effects; however, it 
would be unethical to randomly assign people to receive 
doses of a potentially injurious marker. Thus, methods 
to infer the effect of a potential mediator—for example, 
a plasma marker such as ANG2, a bronchoalveolar 
lavage fluid metabolite, or a whole blood transcript—on 
ARDS risk or mortality are desirable. Once a marker is 
suggested to have a causal role, rigorous experiments 
in model systems should be done to more definitively 
show causality.
Mediation analysis is a formal method to explain the 
mechanism by which a potential explanatory variable 
influences an outcome via an intermediate, or mediator 
variable. Many quantitative traits have a strong genetic 
component; thus, mediation analysis can be applied to 
associations between SNPs and disease outcomes to test 
whether a significant portion of the association is 
mediated by change in a third variable, the quantitative 
trait.86 If the intermediate trait (biomarker, transcript, or 
metabolite) mediates a significant portion of the 
observed risk, this provides good evidence that the 
marker might be mechanistically linked to the disease 
outcome. Wei and colleagues87 used mediation analysis 
to address whether changes in platelet count might 
explain ARDS risk and mortality. They first identified 
genetic variants that strongly influenced baseline platelet 
count during critical illness and then assessed whether a 
SNP strongly associated with platelet count was also 
associated with ARDS risk; they found that a small but 
significant portion of the association between a SNP and 
ARDS was mediated indirectly through changes in 
baseline platelet count. In a related analysis,88 the same 
group used this method to show that a decrease in 
platelet count mediates a portion of ARDS mortality. The 
associations between genetic variants and a quantitative 
trait such as a plasma marker can also be harnessed for 
instrumental variable analysis, whereby SNPs that are 
strongly associated with a biomarker are used to 
genetically predict the biomarker, and then the 
association between the genetically predicted biomarker 
and the outcome is assessed. This approach is sometimes 
called a mendelian randomisation analysis, because 
each individual is considered randomised by random 
assort ment of parental alleles to a genotype that might 
express high or low levels of a biomarker. Mendelian 
randomisation studies have provided strong support for 
the causal contribution of LDL­cholesterol to risk of 
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coronary artery disease; genetic variants associated with 
the plasma concentration of LDL­cholesterol were also 
associated with coronary artery disease, and when the 
concentration of LDL­cholesterol was predicted by 
genotype, genetically predicted LDL­cholesterol was 
associated with this disease.89 Furthermore, dissecting 
the genetic determinants of LDL­C concentration 
has uncovered novel treatment platforms for coronary 
artery disease,89,90 offering an attractive template for 
ARDS genetic research if appropriate intermediates can 
be identified.
Novel preclinical models of ARDS
Another approach to determining the therapeutic 
relevance of pathways identified with ‘omics methods is 
to test them in novel preclinical models of ARDS. 
Although a thorough review of human, animal, and in­
vitro models of lung injury is beyond the scope of this 
Review, several developments that are facilitating the 
translation from bedside to bench and back again are 
worth highlighting and are shown in figures 2 and 3. 
These techniques can interrogate candidates identified 
in bias­free methods with a rigorous experimental 
design and, in some cases, can model treatment, while 
also monitoring the variation in quantitative markers, 
physiology, or gene expression.
A recognised shortcoming in human ARDS research 
is the rarity of lung tissue from acute ARDS, which 
then restricts applications that are cell­specific, such as 
transcriptomic, epigenomic, and proteomic methods. 
One solution to this scarcity of tissue is to use human 
lungs that were declined for transplantation. Up to 
80% of evaluated lungs are deemed unsuitable for 
transplant because of poor oxygenation, visible injury, 
or poor compliance, features that are common to 
ARDS.92,93 Furthermore, to better simulate conditions in 
vivo, these human lungs can be ventilated and perfused 
in an ex­vivo lung perfusion (EVLP) system for several 
hours (figure 2), allowing the observation of physio­
logical measures such as compliance, alveolar fluid 
clearance, and oxygenation and the sampling of lung 
tissue, perfusate, and alveolar fluid.94,95 Clinical trials 
(eg, NCT01365429)92 are being done to test whether 
EVLP can increase the number of suitable lungs for 
transplantation while maintaining optimal transplant 
outcomes. However, these sophisticated systems can 
also be optimal ARDS preclinical models in which to 
screen potential ARDS therapies,94,95 because they have 
the advantages of safety (no human exposure) and 
access to human lung tissue. By taking biopsy samples 
of the tissue and using pharmacological inhibitors or 
agonists, the mechanism of a drug’s action can be 
investigated. The EVLP system can also be adapted 
to model a uniform injury by applying bacteria or 
endotoxin to the lung, making this an adaptable model 
for hypothesis­testing for ARDS prevention and 
therapy.95
Another potential therapeutic screening method uses 
microfluidic bioengineering and three­dimensional cell 
culture to produce a microengineered lung­on­a­chip, 
complete with an alveolar–capillary interface, cyclic 
stretch to mimic breathing, and perfusion to model 
circulation (figure 3).91 Although this system relies on 
human cell lines that are capable of persisting in long­
term culture, and thus, to date, alveolar epithelial cells 
derived from a lung cancer cell line rather than primary 
human alveolar epithelial cells have been used, drug­
induced permeability pulmonary oedema was modelled 
with this system and was shown to share many features 
with clinical toxicity from interleukin 2, including 
reduced oxygen tension and endothelial and epithelial 
paracellular gap formation.91,96 Most impressively, that 
model could be used to test whether co­administration 
of preventive agents—for example, angiopoietin­1 or a 
transient receptor potential cation channel subfamily V 
member 4 channel inhibitor—could block the inter­
leukin 2­mediated permeability and, via immuno­
histochemistry, the mechanism of action could be 
evaluated.91 The microfluidic lung­on­a­chip could also 
be adapted to study therapeutic applications and might 
Figure 2: Ex-vivo lung perfusion system 
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Figure 3: Illustration of a microfabricated lung-on-a-chip
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be considered a more high­throughput method for 
drug screening than EVLP because it does not rely on 
the scarce resource of human lungs. Additionally, if a 
quantitative trait such as a plasma protein concentration 
was identified as having causal significance through 
causal inference modalities or endotype identification, 
then drug screening could proceed with the secreted 
protein as an outcome, improving efficiency. Although 
promising compounds would still need to be tested in 
both small and large animal models of ARDS before 
proceeding to human trials, both EVLP and lung­on­a­
chip microdevices might help to select agents most 
likely to benefit patients.
Finally, the field of genome editing has been 
revolutionised in the past 5 years by the elucidation 
of a family of endonucleases, the clustered regularly 
interspaced short palindromic repeats (CRISPR)/
CRISPR­associated protein (Cas) systems, that are 
capable of site­specific DNA cleavage.97 The simplicity 
by which the CRISPR/Cas9 system can be adapted to 
recognise and cleave a specific genomic sequence has 
been harnessed for gene silencing, to identify 
transcriptional repressors or enhancers, and even to 
insert specific point mutations into the genomes of 
human tissue. To date, CRISPR/Cas9 editing has been 
used to make mice susceptible to the coronavirus 
responsible for Middle East respiratory syndrome, 
overcoming the relative species restriction that Middle 
East respiratory syndrome coronavirus exhibits and 
allowing the testing of potential vaccine and antibody 
treatments.98 Future uses of this technology in ARDS 
could be to interrogate the functional significance of 
poly morphisms or genes identified through genome­
wide association studies or transcriptomic screens, to 
provide or refute evidence for pathogenic causality for 
ARDS biomarkers, and to potentially allow testing of a 
precision paradigm whereby a targeted treatment could 
be tested in different genetic backgrounds.
The next step: biologically informed trials
In this age of rapid technological and analytical 
advances, the promise of matching patients to therapies 
most likely to help, and least likely to harm, seems 
more attainable than at any previous point in history. 
Numerous challenges remain, however, particularly in 
identifying new drug targets and selecting patients 
most likely to benefit. The approaches reviewed here 
have already identified plasma biomarkers that could 
serve as prognostic enrichment factors; markers that 
identify patients more likely to experience ARDS or 
who are at an increased risk of dying if ARDS is 
present.15,19 Enrichment strategies that select such high­
risk patients should improve power for clinical trials by 
ensuring a population with sufficient outcomes to 
analyse a potential treatment effect. If causal inference 
methods or preclinical models of ARDS suggest that a 
marker has a causal role in the development or 
progression of ARDS, then the marker might actually 
identify a biological endotype of ARDS. Endotype­
defining markers might be useful for predictive 
enrichment, whereby a plasma marker could inform 
about a patient’s likely response to a specific therapy.15,17 
As a direct extension, one could then imagine clinical 
trials for which eligibility might be predicated on the 
potential patient expressing a specific plasma marker. 
This approach has been shown to be highly successful 
in cancer therapy, especially when using tumour gene 
expression profiles to select targeted therapy.99,100 In 
asthma, endotype recognition has similarly stimulated 
new therapies that might be more successful when 
restricted to patients predicted to benefit.101
To realise the potential of biomarker­driven clinical 
trials for ARDS, however, a few things must happen.102,103 
First, markers must be rapidly available for hospital 
inpatients to inform potential trial eligibility. By contrast 
with cancer, a biopsy is unlikely to be available for ARDS 
and patients and providers cannot afford to wait long for 
potential genetic results. The technology to measure 
protein biomarkers by ELISA in real time is not a 
technical barrier, but such assays are generally not 
commercially available. Microfluidic cell separation 
coupled with multiplexed, colour­coded probes might 
eventually allow rapid gene expression tests at the 
bedside;104 however, this technology has not been widely 
applied to critical illness.105 Second, biomarker­driven 
trials would require more knowledge about the 
performance of potential plasma markers over time 
during the natural course of ARDS, because the 
concentration of many markers is highly variable by 
time.82,106 Third, in many cases, biomarker­directed trials 
would ideally be preceded by testing of potential therapies 
in preclinical models of ARDS such as EVLP or lung­on­
a­chip, in addition to animal models of ARDS, to better 
predict whether an endotype­defining marker denotes a 
pathway that is modified by the potential therapy. We 
acknowledge that, even when a precision paradigm for 
ARDS is well supported by consistent findings across 
endotype identification, genomic or proteomic profiling, 
and even experimental designs such as EVLP, a potential 
therapy might not improve mortality if it has a deleterious 
effect on a comorbid condition during critical illness or if 
it has utility for ARDS prevention but not progression, 
particularly if ARDS develops rapidly. Well designed 
studies will be needed to selectively target ARDS 
prevention and therapy. Clinical trial considerations are 
addressed more comprehensively in a related review 
about this issue.107
In summary, precision medicine is a realistic paradigm 
for ARDS that could begin to be tested in the near future. 
As ‘omic methods, novel models of lung injury, and new 
analytical approaches improve the resolution of ARDS 
endotypes and suggest new mechanisms of treatment, 
pharmacological breakthroughs might be closer than we 
realise.
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